Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levotofisopam in Hyperuricemia and Gout
NCT01519687Phase 2Unknown
- Sponsor
- Pharmos Corporation
- Start
- Jan 2012
- Primary completion
- Jun 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Levotofisopam in hyperuricemia and gout, sponsored by Pharmos Corporation. Primary endpoint: Percentage reduction in serum urate. Status: unknown.
02
Drugs
Levotofisopam
03
Conditions
hyperuricemiagout
Beyond the preview
Go deeper on NCT01519687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01519687.